View Older Stories View More Recent Stories
-
SOPHiA GENETICS expands AstraZeneca partnership for cancer detection
-
AstraZeneca (AZN) reports Koselugo recommended for approval in the EU by CHMP for plexiform neurofibromas in adults with neurofibromatosis type 1
-
AstraZeneca (AZN) reports Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps
-
AstraZeneca's SAPHNELO subcutaneous trial hits primary endpoint
-
AstraZeneca's Saphnelo shows positive results in lupus trial
-
AstraZeneca's Fasenra fails to meet primary endpoint in COPD trial
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP150.13 at Goldman Sachs
-
AstraZeneca (AZN) PT Raised to $4,925 at UBS
-
Make sure you own this pharma stock: BofA
-
Goldman Sachs Reiterates Conviction Buy Rating on AstraZeneca (AZN:LN) (AZN)
-
Jefferies Reiterates Hold Rating on Mineralys Therapeutics, Inc. (MLYS)
-
AstraZeneca launches home delivery service for nasal flu vaccine
-
SOPHiA GENETICS expands AstraZeneca partnership for AI breast cancer research
-
Trump Posts Letters to Regeneron, Merck, AstraZeneca, GSK, Pfizer, Novo Nordisk, Amgen, Bristol-Myears, AbbVie, Novartis, Gilead, J&J on Truth Social
-
White House: Trump took action on pharma Thursday, sent letters to CEOs
-
AstraZeneca (AZN) Tops Q2 EPS by 108c; reaffirms guidance
-
AstraZeneca receives FDA priority review for IMFINZI in gastric cancer
-
AstraZeneca (AZN) says Trixeo Aerosphere received positive EU CHMP opinion
-
AstraZeneca plans $50 billion US investment by 2030
-
AstraZeneca's TAGRISSO plus chemotherapy extends survival in lung cancer
-
ENHERTU plus pertuzumab gets FDA breakthrough therapy designation
-
AstraZeneca drug meets goals in hypertension trial
-
Summit Therapeutics (SMMT) Is Said In Talks For $15 Billion Partnership With Astra (AZN) - Bloomberg
-
AstraZeneca stock rises amid reports CEO favors US listing move
-
AstraZeneca (AZN) CEO Wants To Move Listing To US - The Times
-
AstraZeneca (AZN) says Datroway approved in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
-
AstraZeneca (AZN) enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
-
UBS identifies stock winners amid structural growth tailwinds
-
Daiichi Sankyo, AstraZeneca (AZN): ENHERTU Plus Pertuzumab Reduced the Risk of Disease Progression or Death
-
AstraZeneca (AZN) Reports ENHERTU plus pertuzumab reduced the risk of disease progression or death by 44% vs. THP
-
Citizens JMP: Standard of Care Modifying Regimens at ASCO 2025
-
Danaher (DHR) Announces Diagnostic Development and Commercialization Partnership to Scale Precision Medicine
-
FDA Mandates Trials For Covid Boosters For Healthy Kids, Adults - NEJM
-
AstraZeneca (AZN) reveals positive results from BATURA Phase 3b trial
-
Airsupra shows significant improvement in asthma treatment, AstraZeneca (AZN) reveals
-
AstraZeneca (AZN) Reports IMFINZI regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTO
-
Bernstein explains why share price rally in this pharma stock should continue
-
AstraZeneca (AZN) reports BREZTRI met primary endpoints in KALOS and LOGOS Phase III trials in asthma
-
AstraZeneca (AZN) Tops Q1 EPS by 139c
-
SOPHiA GENETICS (SOPH) Announces Expanded Collaboration with AstraZeneca to Accelerate Liquid Biopsy Testing Globally from AACR
-
Tempus AI (TEM) Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
-
AstraZeneca is due to report next week. Here's what analysts expect
-
BNP Paribas Exane Starts AstraZeneca (AZN:LN) (AZN) at Outperform
-
Pharma stocks slide after Trump signals tariffs on sector
-
AstraZeneca (AZN) Announces ENHERTU Approved in the EU as First HER2 Directed Therapy for Patients with HR Positive, HER2 Low or HER2 Ultralow Metastatic Breast Cancer
-
AstraZeneca (AZN) reports that AZD0780 demonstrated significant LDL cholesterol reduction in PURSUIT Phase IIb trial
-
AstraZeneca (AZN): IMFINZI approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
-
Goldman Sachs on AstraZeneca (AZN): 'we are positive on the long-term outlook and like the company's strategy'
-
AstraZeneca (AZN:LN) (AZN) PT Raised to GBP151.30 at Goldman Sachs
-
Truist Weighs In on Obesity: 'Catalyst-Rich 2025 Ahead in a Growing Competitive Landscape'
